Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients with a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Principal Investigator
Shu-Yuan Liao, MD
Status
Closed to Accrual
Date Opened To Accrual
February 09 2009
Date Closed to Accrual
August 02 2019
Disease Site
Gynecologic [GY]
Cervix
Phase
I
Developmental Therapeutics
No
Primary Objective
To examine CA-IX, p16, Ki-67, and MCM2 expression in liquid-based cytology (LBC) specimens to see which subset of markers can provide the optimal diagnosis of significant cervical lesions in women in North America with a cytologic diagnosis of atypical glandular cells (AGC) and a positive test for high risk human papillomavirus (HPV). (01/27/14)
To examine high risk HPV, CA-IX, p16, Ki-67, and MCM2 expression in LBC specimens to see which subset of markers can provide the optimal diagnosis of significant cervical lesions in women in Japan and Korea (with each country’s cohort analyzed separately) with a cytologic diagnosis of AGC.
Patient Population
CA-IX, p16, Ki-67, and MCM2 expression in liquid-based cytology (LBC) specimens to see which subset of markers can provide the optimal diagnosis of significant cervical lesions in women in North America with a cytologic diagnosis of atypical glandular cells (AGC) and a positive test for high risk human papillomavirus (HPV).
High risk HPV, CA-IX, p16, Ki-67, and MCM2 expression in LBC specimens to see which subset of markers can provide the optimal diagnosis of significant cervical lesions in women in Japan and Korea (with each country’s cohort analyzed separately) with a cytologic diagnosis of AGC.
Target Accrual
900
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.